Scholarlink

Background <p>Enasidenib, an isocitrate dehydrogenase-2 (IDH2) inhibitor, is indicated for adult patients with relapsed/refractory acute myeloid leukemia (AML) with an IDH2 mutation. This study evaluated the pharmacokinetics (PK) and safety of enasidenib in subjects with hepatic impairment (HI).</p> Methods <p>A multicenter, open-label study assessed the PK of a single 100&#xa0;mg oral dose of enasidenib in subjects with mild (<i>n</i> = 8), moderate (<i>n</i> = 8), and severe (<i>n</i> = 8) HI (Child-Pugh classification) and matched healthy controls (<i>n</i> = 16). Plasma concentrations of enasidenib and its active metabolite, AGI-16,903, were analyzed, and PK parameters were compared between HI groups and healthy controls.</p> Results <p>Following a single oral dose, enasidenib exposure (AUC0-∞) was comparable across all groups, with geometric mean ratios (GMRs) of 97.7%, 96.7%, and 87.4% for mild, moderate, and severe HI versus healthy controls, respectively. Cmax values showed similar trends, with GMRs of 119%, 85.7%, and 86.4% for mild, moderate, and severe HI, respectively. AGI-16,903 exposure decreased with increasing HI severity, with GMRs for AUC0-∞ of 86.3%, 65.0%, and 61.1% for mild, moderate, and severe HI, respectively.</p> Conclusion <p>HI did not significantly alter PK of enasidenib. While AGI-16,903 exposure decreased with increasing HI severity, the impact was not deemed clinically relevant. Taken together, the results of this study support the conclusion that no dose adjustment is warranted for subjects with mild, moderate, or severe HI.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluation of the pharmacokinetics of enasidenib in patients with hepatic impairment

  • 期刊论文

  • 发表日期：

    2025年7月11日

查看全文
  • Yiming Cheng,
  • Jian Chen,
  • Carlos Vigil,
  • Shahram Khanzadeh,
  • Anita Rampersad,
  • Thomas Prebet,
  • Yan Li

摘要

Background

Enasidenib, an isocitrate dehydrogenase-2 (IDH2) inhibitor, is indicated for adult patients with relapsed/refractory acute myeloid leukemia (AML) with an IDH2 mutation. This study evaluated the pharmacokinetics (PK) and safety of enasidenib in subjects with hepatic impairment (HI).

Methods

A multicenter, open-label study assessed the PK of a single 100 mg oral dose of enasidenib in subjects with mild (n = 8), moderate (n = 8), and severe (n = 8) HI (Child-Pugh classification) and matched healthy controls (n = 16). Plasma concentrations of enasidenib and its active metabolite, AGI-16,903, were analyzed, and PK parameters were compared between HI groups and healthy controls.

Results

Following a single oral dose, enasidenib exposure (AUC0-∞) was comparable across all groups, with geometric mean ratios (GMRs) of 97.7%, 96.7%, and 87.4% for mild, moderate, and severe HI versus healthy controls, respectively. Cmax values showed similar trends, with GMRs of 119%, 85.7%, and 86.4% for mild, moderate, and severe HI, respectively. AGI-16,903 exposure decreased with increasing HI severity, with GMRs for AUC0-∞ of 86.3%, 65.0%, and 61.1% for mild, moderate, and severe HI, respectively.

Conclusion

HI did not significantly alter PK of enasidenib. While AGI-16,903 exposure decreased with increasing HI severity, the impact was not deemed clinically relevant. Taken together, the results of this study support the conclusion that no dose adjustment is warranted for subjects with mild, moderate, or severe HI.